On Calciphylaxis, and Ichthyosis

For the answer, click here.

Question 2:

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

A 73-year-old woman with a past medical history of GERD, hypertension, diverticulosis, and recurrent urinary tract infections presented with acute onset of nausea and vomiting. She had left upper quadrant pain that radiated to her left flank. Laboratory studies revealed a serum creatinine level of 1.21 mg/dL; AST and ALT levels, 57 U/L and 53 U/L, respectively; and LDH level, 1053 IU/L. Leukocyte count was 15,700/Î¼L. A contrast-enhanced CT scan of the abdomen showed inhomogeneous uptake of contrast in the left kidney. Paroxysmal atrial fibrillation was noted on an ECG.

NEXT QUESTION »

For the answer, click here.

Question 5:

ANSWER KEY »

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

ANSWER KEY:

Question 1. E

Question 2. B

Question 3. A

Question 4. B

Question 5. C

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Related Content

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

BF% outperforms BMI in Predicting Morality risk in young adults: New Findings / image courtesy of University of Florida

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.

FDA Label Update Positions Inclisiran as First-Line Monotherapy for Hypercholesterolemia

Weight cycling significantly raises heart failure and metabolic disease risks, independent of baseline overweight, underscoring the importance of stable weight strategies.

Related Content

The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment

Inclisiran can now be used without a background statin, as an adjunct to changes in diet and physical activity for reduction of LDL-C in hypercholesterolemia.

FDA Approves Finerenone for Heart Failure With LVEF ≥40% Following Positive Phase 3 Data

Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Weight Cycling Ups Risk for Heart Failure by 50%, Other Metabolic Diseases by Up to 30%: New Data

Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.